(4-苄基苯基)-2-羟基苯甲酸酯 | 85401-80-5

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 缩酚酸和缩酚酸环醚类
• 中文名称: (4-苄基苯基)-2-羟基苯甲酸酯
• 英文名称: salicylic acid-(4-benzyl-phenyl ester)
• 英文别名: Salicylsaeure-(4-benzyl-phenylester)；4-Benzylphenyl 2-hydroxybenzoate；(4-benzylphenyl) 2-hydroxybenzoate
• CAS: 85401-80-5
• 化学式: C₂₀H₁₆O₃
• 分子量: 304.345
• InChiKey: XSGIPGFJYOYADV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-羟基二苯甲烷 、 水杨酸 生成 (4-苄基苯基)-2-羟基苯甲酸酯
  参考文献：
  名称：

  DE68111

  摘要：

  公开号：

文献信息

• COMBINATION OF AN IMMUNOSUPPRESSIVE AGENT AND NONSTEROIDAL ANTI -INFLAMMATORY DRUGS TO TREAT DISEASE
  申请人：Wolfe M. Michael

  公开号：US20090291883A1

  公开（公告）日：2009-11-26

  The present invention provides methods and compositions for the treatment and prevention of neoplasia by administering an effective amount of a NSAID in combination with an effective amount of an immunosuppressant agent. In particular, the present invention provides methods and compositions for the treatment and prevention of neoplasia by administering an effective amount of COX-2 inhibitor in combination with an effective amount of an immunosuppressant agent.

  本发明提供了一种方法和组合物，通过给予有效量的NSAID与有效量的免疫抑制剂来治疗和预防肿瘤。特别地，本发明提供了一种方法和组合物，通过给予有效量的COX-2抑制剂与有效量的免疫抑制剂来治疗和预防肿瘤。
• Pharmaceutical formulations
  申请人：PATRALAN LIMITED

  公开号：EP0366277A2

  公开（公告）日：1990-05-02

  Orally or rectally administrable formulations of biologically active material comprise a water-in-oil microemulsion, wherein the hydrophilic phase of the microemulsion comprises the biologically active material and the hydrophobic phase comprises chylomicra or material capable of forming chylomicra in the intestinal mucosa after administration. The biologically active material may be any of a wide range of substances including insulin, calcitonin and somatotrophin or growth hormone. Formulations of the invention are particularly suitable for the oral administration of insulin in the treatment of diabetes.

  可口服或直肠给药的生物活性物质制剂包括油包水型微乳剂，其中微乳剂的亲水相包括生物活性物质，疏水相包括乳糜或给药后能在肠粘膜中形成乳糜的物质。生物活性物质可以是多种物质中的任何一种，包括胰岛素、降钙素、体液营养素或生长激素。本发明的制剂尤其适用于口服胰岛素治疗糖尿病。
• Expandable gastroretentive dosage form
  申请人：Clexio Biosciences Ltd.

  公开号：US11285102B2

  公开（公告）日：2022-03-29

  An oral gastro-retentive delivery device is provided which unfolds rapidly upon contact with gastric juice. The device is configured in a collapsed configuration for oral intake and unfolding for gastric retention for a predetermined period of time and eventually reducing in size for passage through the rest of the GI track.

  本发明提供了一种口服胃保留给药装置，该装置在与胃液接触后可迅速展开。该装置呈折叠状态，用于口服，展开后可在预定时间内保留在胃中，并最终缩小尺寸，以通过消化道的其余部分。
• CATIONIC POLYMERS AND LIPIDS FOR THE DELIVERY OF NUCLEIC ACIDS
  申请人：——

  公开号：US20010007771A1

  公开（公告）日：2001-07-12

  Novel cationic polymers and cationic lipids, and methods of making and using the same, are provided. The cationic polymers and cationic lipids are useful for the delivery of nucleic acid polymers and oligomers to cells in vitro and in vivo.

  本研究提供了新型阳离子聚合物和阳离子脂及其制造和使用方法。这些阳离子聚合物和阳离子脂质可用于在体外和体内向细胞输送核酸聚合物和寡聚体。
• Delivery vehicles comprising stable lipid/nucleic acid complexes
  申请人：——

  公开号：US20010044147A1

  公开（公告）日：2001-11-22

  Stable polynucleotide delivery vehicles (SPDVs) are described which incorporate a polynucleotide/cationic lipid complex as structural components of the SPDV. The subject SPDVs may optionally incorporate synthetic biodegradable amphipathic lipids, and suitable targeting agents.

  所述稳定的多核苷酸递送载体（SPDV）将多核苷酸/阳离子脂质复合物作为 SPDV 的结构成分。所述 SPDV 还可选择加入合成的可生物降解两性脂质和适当的靶向药剂。